lapatinib has been researched along with Necrosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Werfel, TA | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Balko, JM; Cook, RS; Elion, DL; Gonzales-Ericsson, PI; Hicks, DJ; James, JL; Koblish, HK; Nixon, MJ; Rahman, B; Sanchez, V; Scherle, PA; Werfel, TA | 1 |
| Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H | 1 |
1 trial(s) available for lapatinib and Necrosis
| Article | Year |
|---|---|
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
3 other study(ies) available for lapatinib and Necrosis
| Article | Year |
|---|---|
Assessment of the Immune Response to Tumor Cell Apoptosis and Efferocytosis.
Topics: Animals; Apoptosis; Lapatinib; Macrophages; Mice; Necrosis; Neoplasms; Phagocytosis; Tumor Microenvironment | 2022 |
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Topics: Animals; Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Female; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Necrosis; Phagocytosis; Receptor, ErbB-2; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2019 |
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |